SHR-1905

SHR-1905 is Hengrui's long-acting anti-TSLP monoclonal antibody, currently in Phase 2 for severe uncontrolled asthma (NCT05593250, n=260, enrollment closed) [1]. The differentiation thesis has real evidence behind it now: a published Phase 1 SAD study in healthy volunteers showed a serum half-life of roughly 80-106 days across the 50-600 mg dose range, which the authors state supports every-6-month (Q6M) dosing [10]. That is a step-change compared to tezepelumab's (Tezspire, AstraZeneca/Amgen) Q4W subcutaneous regimen, not a Q8W or Q12W incremental improvement. Hengrui is not waiting for asthma data before broadening the program. A Phase 3 chronic rhinosinusitis with nasal polyps trial launched August 2025 (NCT07132827, n=280) [2] and a Phase 2a atopic dermatitis trial began dosing November 2025 (NCT07211542) [3]. The playbook is transparent: replicate tezepelumab's expansion across TSLP-driven inflammatory diseases with a dramatically longer dosing interval. Tezspire combined global sales were $1.2B in 2024 (AstraZeneca + Amgen), with AstraZeneca recognizing $436M in Alliance Revenue under the profit-share arrangement [4]. If SHR-1905 lands Q6M dosing with tezepelumab-comparable efficacy, it is a credible fast-follower in China and a licensing candidate ex-China, and Hengrui's 2025 BD track record (Merck, GSK) suggests the ex-China path is live.

Novel biologic, no prior regulatory approval anywhere. No public FDA designations (breakthrough, fast track, orphan) have been disclosed, consistent with Hengrui's regulatory strategy running through China's NMPA first before pursuing US filings. Public NMPA IND/CTR filing timelines for the asthma program are not disclosed in English-language sources; the proximate regulatory catalyst is NMPA rather than FDA. NLM's RxNorm has assigned CUI 2670812 for SHR-1905, confirming it as a distinct ingredient in the drug identity registry [5]. The severe asthma Phase 2 (NCT05593250) is listed as active, not recruiting, meaning the 260-patient cohort is fully enrolled and the trial is now in follow-up and endpoint adjudication [1]. Given a 52-week AAER primary endpoint window, topline readout is likely late 2026. Hengrui's decision to open a Phase 3 nasal polyps trial (NCT07132827, actual start 2025-08-28) [2] before the asthma Phase 2 has read out signals internal confidence in the Phase 1 pharmacokinetic and safety data, which were published in Frontiers in Pharmacology in 2024 [10]. A separate adolescent Phase 2 PK study (NCT06786455) has already completed, providing bridging data for younger patients [6].

TSLP (thymic stromal lymphopoietin) is a cytokine, a signaling protein, released by cells lining the airway when they encounter allergens, viruses, or air pollutants [7]. Think of it as an alarm bell sitting at the top of the allergic inflammation cascade. Once released, TSLP activates dendritic cells and mast cells, which then recruit eosinophils, drive IgE production, and cause the airway inflammation that defines severe asthma [7]. Blocking TSLP shuts down the alarm before it triggers the full downstream response, so a single anti-TSLP antibody can dampen multiple inflammation pathways at once instead of hitting just eosinophils (mepolizumab, benralizumab) or just IgE (omalizumab). The mechanism is well-validated. Tezepelumab, the first approved anti-TSLP antibody, cut annual asthma exacerbations by 56% versus placebo in the NAVIGATOR Phase 3 trial, and the benefit held regardless of baseline eosinophil count [8]. That is the piece that makes TSLP commercially interesting: existing biologics require patients to have high eosinophils or high IgE to work. Anti-TSLP works in the broader severe asthma population that current biologics leave behind. Open Targets scores TSLP at 0.72 for asthma, near the top of the genetic and clinical evidence for this disease. Note for MOA comparisons in the competitive discussion: SHR-1905 and tezepelumab both neutralize the TSLP cytokine (the ligand). Upstream Bio's verekitug, often grouped in the same class, actually binds the TSLP receptor (TSLPR) and blocks receptor signaling rather than sequestering the ligand [9]. These are distinct pharmacologies with potentially different failure modes and breadth of pathway blockade.

NCT05593250 is a Phase 2 study of SHR-1905 in severe uncontrolled asthma, enrolling 260 subjects with the annual asthma exacerbation rate (AAER) as primary endpoint [1]. AAER is the standard efficacy measure for severe asthma biologics, the same endpoint used in NAVIGATOR for tezepelumab [8], so the readout will be directly comparable to the class benchmark. The trial is sponsored by Shanghai Hengrui Pharmaceutical and is now active but not recruiting, meaning the 260-patient cohort is fully enrolled. What is not in the public record: exact Phase 2 dosing interval and dose level, comparator arm (placebo assumed but not confirmed on the registry entry), and whether the trial pre-specifies stratification by baseline eosinophil count. The eosinophil-independent effect was tezepelumab's key differentiator, and if Hengrui's protocol does not pre-specify that subgroup analysis, the commercial value of the readout will be limited. The Phase 1 study used single doses of 50-600 mg with follow-up to Day 253, so any Phase 2 dosing schedule shorter than Q3M would be surprising given the observed half-life [10]. The parallel Phase 3 in nasal polyps (NCT07132827, n=280, primary completion April 2028) enrolls a smaller, more homogeneous population where Type 2 inflammation is the dominant driver, giving Hengrui two independent efficacy signals in overlapping timeframes [2]. Opening a Phase 3 before Phase 2 asthma data reads out is an aggressive design choice, but the published Phase 1 safety and PK data provide more scaffolding for that decision than the registry entries alone would suggest.

Our model estimates a 6% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual; it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is moderate but bounded. TSLP is validated, so a failure to hit AAER is more likely to reflect molecule-specific issues (dose selected, immunogenicity, receptor engagement kinetics) than target failure. The harder efficacy question is differentiation: tezepelumab, mepolizumab, benralizumab, dupilumab, and omalizumab are all approved for severe asthma. Q6M dosing, if it holds up in Phase 2, is a real wedge; anything shorter than Q3M would erode most of the commercial thesis. Safety risk looks manageable. Anti-TSLP has been clean across tezepelumab's development, no black-box warnings, no class-wide toxicity signals of concern [8]. SHR-1905's own Phase 1 SAD study reported mild TEAEs comparable to placebo across 50-600 mg [10]. TSLP does have roles in mucosal immunity, so multi-year suppression could theoretically raise infection risk, and Phase 3 programs will monitor infection rates closely. Execution risk is where this gets interesting. Hengrui is a competent Chinese pharma with deep antibody manufacturing experience, and the ex-China commercialization pathway is more credible than it was 18 months ago: the Merck MK-7262 deal (May 2025, $200M upfront, up to $1.77B in milestones) and the GSK deal (July 2025, ~$12B potential across 12 respiratory/immunology/oncology programs) show a functioning outbound licensing channel [11][12]. The anti-TSLP-pathway market ex-China is contested. Upstream Bio, Inc. (Nasdaq: UPB) is developing verekitug (UPB-101), which targets the TSLP receptor rather than the TSLP cytokine and is in Phase 2 for severe asthma with its own long-acting pitch [9]. Verekitug is further along outside China and is the direct competitor for the 'less-frequent-dosing anti-TSLP-pathway biologic' positioning, though the mechanistic difference (receptor blockade vs cytokine neutralization) means the two assets could show different safety or subgroup profiles. Commercial risk: US payers already restrict severe asthma biologic uptake through step therapy. A me-too, even with dramatically better dosing, faces immediate access friction unless a Phase 3 shows clean differentiation in a defined patient segment. Tezepelumab's US composition-of-matter patent estate runs into the 2030s (specific expiry not verified against public patent records here), so the ex-China commercial window for a fast-follower is meaningful but not indefinite.

Worth watching, arguably worth chasing selectively. The Phase 1 PK data materially strengthen the thesis: a ~80-106 day half-life supporting Q6M dosing [10] is not a marginal Q4W-to-Q8W improvement, it is a category shift in patient convenience for a chronic biologic. The signal to look for is the Phase 2 AAER readout from NCT05593250, likely late 2026 [1]. If Hengrui reports a 50%+ reduction versus placebo, comparable to tezepelumab, plus confirmation that the Phase 2 used a Q3M-or-longer schedule, this becomes a strong fast-follower asset with real licensing value. If it comes in at 35-45% reduction and the dosing schedule turns out shorter than the PK would suggest, it is a China-domestic asset with limited ex-China pull. The nasal polyps Phase 3 (NCT07132827) is arguably the more important trial for near-term valuation because it is the first anti-TSLP-ligand test in CRSwNP where dupilumab currently owns the biologic franchise [2]. A positive readout there would open a multi-billion dollar addressable segment for Hengrui. Watch that trial as carefully as the asthma one. Central unresolved assumption to flag for readers: SHR-1905's Phase 2 dosing interval is not disclosed in the ClinicalTrials.gov entry, and the 'Q6M in the clinic' inference rests on the Phase 1 PK paper's own author-stated implication, not on a released Phase 2 protocol or Hengrui presentation. Until dosing interval is confirmed in a company disclosure or the Phase 2 readout, this is the single most important open variable in the thesis. Company context: Hengrui has been actively out-licensing antibody and small-molecule assets to global partners at scale in 2025 [11][12]. SHR-1905 fits the same profile, a China-developed asset positioned for ex-China licensing conversations after Phase 2 proof of concept. Next check-in: Q4 2026 for the asthma AAER topline.